Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Expands By 116.7%

AstraZeneca PLC (OTCMKTS:AZNCF) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 127,400 shares, an increase of 116.7% from the December 15th total of 58,800 shares. Based on an average trading volume of 8,500 shares, the days-to-cover ratio is currently 15.0 days.

Hedge Funds Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,001 shares of the company’s stock, valued at approximately $156,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $131.27 on Tuesday. AstraZeneca has a 12-month low of $118.16 and a 12-month high of $175.00. The company’s fifty day simple moving average is $131.32 and its two-hundred day simple moving average is $148.60.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.